Carlsmed, Inc. (CARL)
Nasdaq · Healthcare · Health Information Services
$15.30+7.22%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $418M
- 52-week range
- $8.50 – $17.23
- 52-week change
- −1.45%
- EPS (trailing)
- −$1.16
- Analyst rating
- 1.4 Strong buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $50.5M (+85.94%)
- Net income
- −$29.6M
- Operating margin
- −60.5%
- Diluted EPS
- −$2.12
- Free cash flow
- −$29.6M
From the company’s annual report on SEC EDGAR.
About Carlsmed, Inc.
Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting custom-built, anatomically designed vertebral interbody implants. The company was incorporated in 2018 and is based in Carlsbad, California.
Headquarters: Carlsbad, United States · 127 employees · carlsmed.com